NAD+ precursors (NR and NMN): what the human trials actually show

NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — are among the most heavily marketed longevity supplements. The pitch is seductive: NAD+ declines with age, these compounds raise it, therefore they should slow aging. The first two links in that chain have real human evidence. The third — that raising NAD+ actually extends healthspan in people — does not. That gap is the most important thing to understand here.

Step one: do they actually get into you?

This part is genuinely established. A controlled human study showed that oral nicotinamide riboside is bioavailable and raises the blood NAD+ metabolome in a dose-dependent way — the precursor is absorbed and converted to NAD+ as the biochemistry predicts.^[1] So the foundational claim, “NR gets into your bloodstream and feeds the NAD+ pathway,” is supported by human data, not just cell-culture hope.

Step two: do they raise NAD+ and are they safe short-term?

A randomized, placebo-controlled trial in healthy middle-aged and older adults found that chronic NR supplementation was well-tolerated and effectively elevated NAD+ in blood.^[2]The trial also explored cardiovascular measures such as blood pressure and arterial stiffness, with suggestive but not definitive signals. The honest read: NR reliably raises the biomarker and looks safe over the studied period, but the downstream physiological benefits were exploratory, not confirmed endpoints.

NMN: one provocative trial, much hype

NMN's most-cited human study randomized prediabetic, postmenopausal women to NMN or placebo and reported improved skeletal-muscle insulin sensitivity in the NMN group.^[3] It is a real, peer-reviewed randomized result — but it is one small trial, in a specific population, measuring a surrogate (insulin sensitivity) rather than a clinical outcome, and it generated published scientific debate. A separate randomized trial in amateur runners reported improved aerobic capacity with NMN.^[4] These are interesting, but they are small, surrogate-endpoint studies — not evidence that NMN makes people live longer or healthier in any durable, demonstrated sense.

The leap the marketing makes

Here is the load-bearing distinction. Raising a biomarker (NAD+) is not the same as improving an outcome (healthspan, disease, lifespan). The human trials credibly establish that NR and NMN raise NAD+ and appear safe in the short term, and a couple of small trials show surrogate-marker improvements. None of them demonstrate that these supplements slow human aging, prevent disease, or extend life. The animal data that fuel the excitement have repeatedly failed to translate cleanly into human outcomes for other longevity compounds, and there is no reason to assume NAD+ precursors are exempt.

The honest bottom line

The evidence tier for NAD+ precursors in humans is preliminary and surrogate-marker level. What is well-supported: NR is bioavailable, raises NAD+, and is well-tolerated short-term; NMN shows a few small surrogate-endpoint signals. What is not supported by human data: any claim about longevity, healthspan, or disease prevention. If you take these compounds, take them knowing you are betting on a plausible mechanism with a measured biomarker — not on a proven clinical benefit.